Global In-vitro Fertilization Market Forecast 2017-2026
KEY FINDINGS Global In-vitro fertilization market is expected to showcase a healthy CAGR growth of 10.50% over the forecast period of 2017 – 2026. The market growth is chiefly driven by growing infertility rates across the globe. Factors like improved surrogacy laws and high success rate of IVF treatments are further boosting the market expansion.
MARKET INSIGHTS Products, procedures, and end-users are the primary market segments of the global IVF market. The product segment of this market comprises of equipments and reagents. The various IVF procedures considered for the market includes frozen embryo transfer/replacement, pre-implantation genetic diagnosis, and intra-cytoplasmic sperm injection. The end-users for the market are hospitals and research laboratories, cryobanks and fertility and surgical centers.
REGIONAL INSIGHTS The regional segmentation of the global IVF market is done into North America, Asia, Europe and rest of the world. Europe and Asia-Pacific are the two regions of the global in-vitro fertilization market that have gained significant importance in recent years. The former market dominated the global scene in 2016 while the latter is predicted to evolve with the fastest CAGR over the forecast period. The European market is mainly propelled by proper government support and rising healthcare expenditure for the IVF market. In the present scenario, the region is also witnessing a sharp rise in the infertility rates, which, in turn, is augmenting the market growth.
COMPETITIVE INSIGHTS Global companies involved in the in-vitro fertilization market are Auxogyn, Cook Medical Inc, Andrology Solutions, Copper Surgical Inc, Ferring Pharmaceuticals, Esco Micro Pte. Ltd, Genea, Irvine Scientific (Subsidiary Of Nippon Mining Holdings), Halotech DNA, Ivftech Aps, Ovascience, Merck Serono, The Baker Company Inc, Vitrolife Ab and Thermo Fisher Scientific Inc.